Emerging antiplatelet and lipid lowering therapies

n/

Myocardial perfusion imaging in very elderly patients with suspected coronary artery disease: Never too late!

n/

The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues.

β-blockers represent a mainstay in the pharmacological approach to patients affected by heart failure with reduced ejection fraction (HFrEF). However, underuse of this class of drugs is still reported, especially in the presence of cardiovascular and non-cardiovascular comorbidities, even if they are not contraindications for prescription of a β-blocker. The prognostic benefit of β-blockers is relevant in the presence of comorbidities, and achievement of the maximum tolerated dose is an important goal to increase their favorable prognostic role. The aim of the present review is to analyze the available evidence on the use of β-blockers in HFrEF patients with the most common comorbidities. In particular, we will discuss the role and most appropriate beta-blocker in patients with pulmonary disease (bisoprolol, metoprolol, nebivolol), diabetes (carvedilol and nebivolol), atrial fibrillation (all indicated for rate control, with metoprolol as the first choice followed by bisoprolol, nebivolol, and carvedilol), erectile dysfunction (bisoprolol and nebivolol), peripheral arterial disease (nebivolol), and other conditions, in order to clarify the correct use of this class of drugs in the clinical practice

Effects of regional systolic asynchrony on left ventricular global diastolic function in patients with coronary artery disease

AbstractPatients with coronary artery disease often have impaired left ventricular diastolic filling despite normal global systolic function. The influence of regional systolic asynchrony on diastolic function was assessed by radionuclide angiography in 60 patients with coronary artery disease and normal ejection fraction at rest: group 1 (n = 30) with normal wall motion at rest and group 2 (n = 30) with abnormal wall motion. Data were compared with those obtained from 19 normal volunteers.Age, heart rate, ejection fraction and echocardiographic enddiastolic dimension did not differ among the three groups. Peak filling rate in group 1 and group 2 was similar (2.5 ± 0.5 and 2.3 ± 0.6 end-diastolic counts/s, respectively) and significantly lower than that in the normal subjects (2.8 ± 0.7 end-diastolic counts/s; p < 0.01 vs. group 2, p < 0.05 vs. group 1). Time to peak filling rate was prolonged in group 2 (184 ± 27 ms) compared with that in normal subjects (162 ± 19 ms; p < 0.01) and group 1 (172 ± 15 ms; p < 0.05). Left ventricular end-diastolic pressure was significantly higher in group 2 than in group 1 (14 ± 7 vs. 10 ± 5 mm Hg, respectively; p < 0.05).Asynchrony was assessed by sector analysis of the radionuclide left ventricular region of interest. Diastolic asynchrony was similar in the two patient groups (30 ± 23 ms in group 2, 26 ± 16 ms in group 1) and was higher in both groups than in the normal subjects (16 ± 8 ms; p < 0.61). However, systolic asynchrony was higher in group 2 (32 ± 15 ms) than in both group 1 (14 ± 6 ms; p < 0.01) and the normal group (9 ± 6 ms; p < 0.01). In the total group of patients with coronary artery disease, systolic asynchrony correlated with global time to peak filling rate (r = 0.53; p < 0.001). This correlation became stronger when only group 2 was considered (r = 9.62; p < 0.001). Moreover, in group 2 systolic asynchrony correlated with the duration of the isovolumetric relaxation period (r = 0.58; p < 0.001) and the isovolumetric relaxation period, in turn, correlated with global time to peak filling rate (r = 0.72; p < 0.001).Thus, left ventricular systolic asynchrony affects both the relaxation and filling phases of diastole, thereby contributing to the impairment of diastolic function commonly observed in patients with coronary artery disease

How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion

Obesity is an important independent cardiovascular (CV) risk factor and a chronic inflammatory disease related to the development of insulin resistance, type 2 diabetes, dyslipidaemia, coronary artery disease, hypertension, heart failure, atrial fibrillation and obstructive sleep apnoea. Body Mass Index (BMI) values >27 Kg/m2 are associated with an exponential increase in the risk for Major Adverse Cardiac Events (MACE). On the other hand, weight reduction can significantly reduce metabolic, CV and oncological risk. Orlistat, bupropion/naltrexone, liraglutide and semaglutide, combined with lifestyle changes, have proven to be effective in weight loss; the last two have been tested in randomized clinical trials (RCTs) with CV outcomes only in diabetic patients, and not in obese patients. To fill a fundamental gap of knowledge, the SELECT trial on patients with obesity and CV disease treated with semaglutide is ongoing, aiming at MACE as the primary endpoint. The battle against the social and clinical stigma towards obesity must be counteracted by promoting an awareness that elevates obesity to a complex chronic disease. Several actions should be implemented to improve the management of obesity, and cardiologists have a key role for achieving a global approach to patients with excess weight also through the correct implementation of available treatment strategies

Metabolic evidence of viable myocardium in regions with reduced wall thickness and absent wall thickening in patients with chronic ischemic left ventricular dysfunction

AbstractReduced end-diastolic wall thickness with absent systolic wall thickening has been reported to represent nonviable myocardium in patients with chronic coronary artery disease. To assess whether reduced regional end-diastolic wall thickness and absent wall thickening accurately identify nonviable myocardium, 25 patients with ischemic left ventricular dysfunction (ejection fraction at rest 27 ± 10%) underwent positron emission tomography with oxygen-15-labeled water and 18fluorodeoxyglucose to assess metabolic activity and spin-echo gated nuclear magnetic resonance imaging to measure regional end-diastolic wall thickness and wall thickening. The presence of metabolic activity was defined as 18fluorodeoxyglucose uptake (corrected for partial volume) >50% of that in normal regions.Of 355 myocardial regions evaluated, 266 were hypokinetic or normokinetic at rest and 89 were akinetic (that is, absent wall thickening). 18Fluorodeoxglucose uptake was observed in 97% of the hypokinetic and normokinetic regions and in 74% of the akinetic regions. End-diastolic wall thickness was greater in akinetic regions with than in those without 18fluorodeoxyglucose uptake (11 ± 4 vs. 7 ± 3 nun, p < 0.01). The highest values for sensitivity and specificity of end-diastolic wall thickness in predicting the absence of metabolic activity in akinetic regions were 74% and 79%, respectively, and corresponded to an end-diastolic threshold of 8 mm. However, the positive predictive accuracy was only 55% and did not improve for other end-diastolic wall thickness values. In all myocardial regions, there was only a weak correlation between 18fluorodeoxyglucose activity and either end-diastolic wall thickness (r = 0.17) or wall thickening (r = 0.32).Thus, metabolic activity is present in many regions with reduced end-diastolic wall thickness and absent wall thickening. These data indicate that assessment of regional anatomy and function may be inaccurate in distinguishing asynergic but viable myocardium from nonviable myocardium